OLX-07010 for Alzheimer's Disease Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults (18-50 of age inclusive), and single dose in healthy elderly (51-75 of age inclusive). The effects of dosing with or without food in healthy adults will also be studied (optional).
Are You a Good Fit for This Trial?
Healthy adults aged 18-50 and healthy elderly individuals aged 51-75, all of non-childbearing potential, can participate. They must have a stable weight within certain BMI ranges and no significant medical history or current conditions that could affect the study drug's processing in the body.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Single Ascending Dose (SAD)
Participants receive single ascending doses of OLX-07010 to evaluate safety, tolerability, and pharmacokinetics
Multiple Ascending Dose (MAD)
Participants receive multiple ascending doses of OLX-07010 to evaluate safety, tolerability, and pharmacokinetics
Food Effect Study (Optional)
Participants receive OLX-07010 with and without food to evaluate the effect of food on drug pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- OLX-07010
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oligomerix, Inc
Lead Sponsor